Alan B. Sandler

Yale University — United States

Medicine · Health Sciences

49h-index9.8kcitations132works0.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(81), Lung Cancer Research Studies(45), Lung Cancer Diagnosis and Treatment(30), Cancer Treatment and Pharmacology(17), Cancer therapeutics and mechanisms(17)

Publications131 total

Prevalence of Mood and Anxiety Disorders in Individuals at Clinical High Risk for Psychosis: A Comparison with Youth at Risk for Bipolar Disorder
2026Open Access
1323MO ASPEN-03: A randomized phase II study of evorpacept in combination with pembrolizumab in patients with recurrent, unresectable or metastatic (R/M) PD-L1 positive head and neck squamous cell carcinoma (HNSCC)
Annals of Oncology·2025
623TiP A single-arm phase 2 study of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic breast cancer (mBC) (ASPEN-09-03)
Annals of Oncology·2025Open Access
1324MO ASPEN-04: A randomized phase II study of evorpacept in combination with pembrolizumab and chemotherapy in patients with recurrent, unresectable or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Annals of Oncology·2025
Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer
The Oncologist·2025· 1 citedOpen Access
Supplementary Figure S1 from Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study
2023Open Access
Data from Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study
2023Open Access
Data from Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study
2023Open Access
Supplementary Figure S1 from Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study
2023Open Access
Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer
UNC Libraries·2021Open Access
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Cancer Treatment Reviews·2020· 1.1k cited
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer
American Journal of Clinical Oncology·2015· 51 citedOpen Access
Body Mass Index and Its Association with Clinical Outcomes for Advanced Non–Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials
Journal of Thoracic Oncology·2013· 110 citedOpen Access
EGFR Tyrosine Kinase Inhibitors: Difference in Efficacy and Resistance
Current Oncology Reports·2013· 25 cited
The Role of MET Receptor Tyrosine Kinase in Non-Small Cell Lung Cancer and Clinical Development of Targeted Anti-MET Agents
The Oncologist·2013· 75 citedOpen Access
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
Annals of Oncology·2012· 311 citedOpen Access
Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab
Journal of Thoracic Oncology·2012· 62 citedOpen Access
Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer
Clinical Lung Cancer·2012· 126 citedOpen Access
Beyond Bevacizumab: Antiangiogenic Agents
Clinical Lung Cancer·2012· 21 cited
Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab
Lung Cancer·2012· 38 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Joan H. Schiller(13), David H. Johnson(11), Roy S. Herbst(7), Julie R. Brahmer(6), Corey J. Langer(6), Suzanne E. Dahlberg(5), David H. Johnson(5), Suresh S. Ramalingam(4), Chandra P. Belani(4), Mark A. Socinski(4), David M. Dilts(4), Afshin Dowlati(3), Robert J. Gray(3), David P. Carbone(3), Bruce E. Johnson(3), Diane Prager(3), Róbert Hermann(3), P C Hoffman(3), Steven K. Cheng(3), Joachim von Pawel(2)